Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis

Summary

This study will investigate an experimental new drug, GSK1223249 in patients diagnosed with relapsing forms of multiple sclerosis. The study will specifically investigate safety (vital signs like heart rate, blood pressure, Magnetic Resonance Imaging (MRI), and other markers of health from blood samples), tolerability (any side effects that occur, if any), and pharmacokinetics (how the body processes the drug and how long the drug stays in the blood, and in cerebro-spinal fluid). The study will also investigate if patients' own immune system interacts with GSK1223249.

Timeline

Start

2011-09-08

Primary completion

2012-01-23

Completion

2012-01-23

Drugs

Indications